Ascelia Pharma’s new share issue in connection with the IPO on Nasdaq Stockholm was significantly oversubscribed

by | Mar 7, 2019

The offering in Ascelia Pharma AB (“Ascelia Pharma” or the “Company”) in connection with the Initial Public Offering on Nasdaq Stockholm was significantly oversubscribed.

The new share issue (the “Offering”) will provide Ascelia Pharma with approximately SEK 200 million before deductions for expenses related to the Offering.

 

Press inquiries should be adressed to:

Peter Benson, Msc

Chairman & General Partner